-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Nektar Therapeutics quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2010 to 2023.
- Nektar Therapeutics Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $46K.
- Nektar Therapeutics Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was -$79K, a 103% decline year-over-year.
- Nektar Therapeutics annual Income Tax Expense (Benefit) for 2023 was -$200K, a 106% decline from 2022.
- Nektar Therapeutics annual Income Tax Expense (Benefit) for 2022 was $3.22M, a 477% increase from 2021.
- Nektar Therapeutics annual Income Tax Expense (Benefit) for 2021 was $557K, a 13% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)